Skyrizi vs Stelara
Side-by-side cost comparison based on Medicare Part D data
Skyrizi
Risankizumab
Manufactured by AbbVie
Stelara
Ustekinumab
Manufactured by Janssen
Skyrizi costs 42% less per claim than Stelara ($4,475.00 vs $7,763.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Skyrizi | Stelara |
|---|---|---|
| Avg Cost Per Claim | $4,475.00 | $7,763.00 |
| Total Medicare Spending | $2.3B | $5.6B |
| Total Beneficiaries | 78,000 | 114,000 |
| Total Claims | 524,000 | 720,000 |
| Annual Cost/Patient | $30,064.00 | $49,026.00 |
| Year-over-Year Change | +42.8% | +6.3% |
| Generic Available | No | Yes |
| Patent Expiration | Apr 23, 2035 | Jan 31, 2023 |
| Manufacturer | AbbVie | Janssen |
| Condition | Autoimmune Diseases | Autoimmune Diseases |
| Generic Name | Risankizumab | Ustekinumab |
Skyrizi vs Stelara: What the Data Shows
Skyrizi (Risankizumab) and Stelara (Ustekinumab) are both used to treat autoimmune diseases. Based on Medicare Part D data, Skyrizi costs $4,475.00 per claim, which is 42% less than Stelara at $7,763.00 per claim.
Medicare spent $2.3B on Skyrizi and $5.6B on Stelara. In terms of patient reach, Stelara serves more beneficiaries (114,000 vs 78,000).
Year-over-year spending changed +42.8% for Skyrizi and +6.3% for Stelara. Skyrizi saw significant spending growth, suggesting increased utilization or price increases.
Stelara has a generic available, while Skyrizi remains brand-only until its patent expires Apr 23, 2035.
Frequently Asked Questions
Skyrizi is cheaper at $4,475.00 per claim, compared to $7,763.00 for Stelara. That makes Skyrizi about 42% less expensive per claim based on Medicare Part D data.
Yes, both Skyrizi and Stelara are used to treat autoimmune diseases. Your doctor can help determine which medication is more appropriate for your specific situation.
Stelara has a generic version (Ustekinumab) available, which is typically much cheaper. Skyrizi is currently brand-only, with patent expiring Apr 23, 2035.
Medicare Part D spent $2.3B on Skyrizi covering 78,000 beneficiaries, and $5.6B on Stelara covering 114,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.